Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma
| Autor: | Saif Ullah, Bing-Rong Liu, Suliman Khan, Ji-Yu Zhang, Ruizhe Li, Yang Shi, Siran Zhou, Zheng Xiang, Huiyu Yang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Aging
Esophageal Neoplasms tensin-3 Cell Survival medicine.drug_class medicine.medical_treatment Mice Nude histone deacetylase inhibitors medicine.disease_cause LMK-235 Targeted therapy In vivo Cell Line Tumor Tensins Animals Humans Medicine Gene silencing RNA Small Interfering neoplasms Cell Proliferation Mice Inbred BALB C biology Cell growth business.industry Histone deacetylase inhibitor histone acetylation Oncogenes Cell Biology digestive system diseases esophageal squamous cell carcinoma Gene Expression Regulation Neoplastic Phenotype Histone Databases as Topic Acetylation Benzamides Cancer research biology.protein business Carcinogenesis Research Paper |
| Zdroj: | Aging (Albany NY) |
| ISSN: | 1945-4589 |
| DOI: | 10.18632/aging.203091 |
| Popis: | Histone acetylation which regulates about 2-10% of genes has been demonstrated to be involved in tumorigenesis of esophageal squamous cell carcinoma (ESCC). In this study, we investigated the treatment response of ESCC to selective histone deacetylase inhibitor (HDACi) LMK-235 and potential biomarker predicting the treatment sensitivity. We identified tensin-3 (TNS3) which was highly over-expressed in ESCC as one of the down-regulated genes in response to LMK-235 treatment. TNS3 was found positively correlated with the tumor malignancy and poor prognosis in the patients. Silencing TNS3 significantly inhibited ESCC cell proliferation both in vitro and in vivo, sensitizing the treatment response to LMK-235. Our findings provide an insight into understanding the oncogenic role of TNS3 in ESCC and its clinical application for HDAC targeted therapy of ESCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|